In This Article:
As global markets experience a broad-based rally, with U.S. indexes nearing record highs and smaller-cap stocks outperforming their larger counterparts, investor sentiment is buoyed by strong labor market data and positive housing reports. Amidst this backdrop of economic optimism, growth companies with high insider ownership can be particularly appealing as they often signal management's confidence in the company's potential to navigate current uncertainties and capitalize on opportunities for expansion.
Top 10 Growth Companies With High Insider Ownership
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.4% | 37.3% |
Seojin SystemLtd (KOSDAQ:A178320) | 31.1% | 43.2% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.3% |
SKS Technologies Group (ASX:SKS) | 32.4% | 24.8% |
Medley (TSE:4480) | 34% | 31.7% |
Findi (ASX:FND) | 34.8% | 71.5% |
Plenti Group (ASX:PLT) | 12.8% | 120.1% |
Fulin Precision (SZSE:300432) | 13.6% | 66.7% |
Brightstar Resources (ASX:BTR) | 16.2% | 84.6% |
Global Tax Free (KOSDAQ:A204620) | 19.9% | 67.5% |
We'll examine a selection from our screener results.
Pharmanutra
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pharmanutra S.p.A. is a pharmaceutical and nutraceutical company that focuses on researching, designing, developing, and marketing nutritional supplements and medical devices across Italy, Europe, the Middle East, South America, the Far East, and internationally with a market cap of €532.28 million.
Operations: The company's revenue segments are comprised of €5.49 million from Akern, €68.35 million from Italy, and €38.40 million from international markets outside Italy.
Insider Ownership: 10.7%
Earnings Growth Forecast: 18.5% p.a.
Pharmanutra's recent earnings report shows strong growth, with sales reaching €83.47 million for the first nine months of 2024, up from €71.43 million a year ago. The company's revenue and net income have also increased significantly, reflecting robust financial health. Although insider trading data over the past three months is unavailable, analysts agree on a potential stock price rise of 52.2%. Pharmanutra's earnings are forecast to grow at 18.5% annually, outpacing the Italian market average of 7.3%.
-
Delve into the full analysis future growth report here for a deeper understanding of Pharmanutra.
-
Upon reviewing our latest valuation report, Pharmanutra's share price might be too optimistic.
Geo Energy Resources
Simply Wall St Growth Rating: ★★★★★★
Overview: Geo Energy Resources Limited is an investment holding company involved in the mining, production, and trading of coal with a market cap of SGD378.49 million.